Oncology Drug Database
Welcome to the online oncology drug search engine!
Drugs are indexed by their FDA-approved name, not brand or generic names (e.g., trastuzumab, not Herceptin). Database last updated: May 5, 2008
NEW USERS: Register and get immediate access to the Oncology Drug Database
Note: This database is separate from the ACCC-member database. Registering here for the Oncology Drug Database does not automatically allow entrance to the ACCC Members-only section.
ACCC's Compendia-Based Drug Bulletin Awaits CMS Clarification
In July 2007, one of the recognized drug compendia, the United States Pharmacopeia's USP DI Drug Information for the Health Care Professional, was succeeded by Thomson Healthcare’s DrugPoints®. Because CMS has yet to provide clarity with regards to indications as they appear in DrugPoints®, ACCC is currently not in the position to print the November 2007 edition of its Compendia-Based Drug Bulletin. Once information is provided by CMS, we will once again provide the Drug Bulletin. We know the importance of the Drug Bulletin and apologize for any inconvenience experienced during this transition period. We will continue to keep you abreast of developments with DrugPoints® as we learn them. For more information, please contact Donald Jewler, Director, ACCC Corporate Communications, at djewler@accc-cancer.org.
Compendium Update: Changes to USP DI Drug Information
Starting July 2007 one of the recognized drug compendia, the United States Pharmacopeia's USP DI Drug Information for the Health Care Professional, was succeeded by Thomson Healthcare's DrugPoints®. As of October 12, 2007, ACCC is including information from DrugPoints®.
DrugPoints® uses a new rating system for indications. The three-tier rating system will include three evidence-based rating categories for FDA-labeled and off-label indications. Indications will be assigned one rating from each of the three categories:
- Efficacy (Class I–III, with I being Effective and III being Ineffective)
- Strength of Recommendation (Class I–III, with I being Recommended and III Not Recommended)
- Strength of Evidence (Category A–C)
As part of the transition from USP DI to DrugPoints®, more than 14,000 indications were reconciled across the two products and those USP DI off-label indications were reviewed and assigned the appropriate ratings in DrugPoints®. There is not be a one-to-one correlation between the USP DI Acceptance Rating and the DrugPoints® ratings.
Note: ACCC's Reimbursement Committee is reviewing the new ratings and will change the Association's own Compendia-based Drug Bulletin as appropriate.
DrugPoints® online is a copyrighted database of Micromedex, Inc. All rights reserved. DrugPoints® System [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Updated periodically.
TERMS AND CONDITIONS
Information is for Authorized End User's use only and may not be sold, redistributed, or otherwise used for commercial purposes.
The information contained in DrugPoints® is intended as an educational aid only. All treatments or procedures are intended to serve as an information resource for physicians or other competent healthcare professionals performing the consultation or evaluation of patients and must be interpreted in view of all attendant circumstances, indications, and contraindications.
The use of DrugPoints® is at your sole risk. The product is provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Micromedex and the Association of Community Cancer Centers do not assume any responsibility or risk for your use of the Micromedex product. Your local Medicare carrier has final say on which indications it will accept.
Useful Tips:
- You can view your search results in a separate popup window without actually leaving our web site.
- You can print your search results from inside the popup by right-clicking and choosing the Print command (for Internet Explorer 4+ browsers) or by clicking Ctrl+P (for Netscape Navigator 4+, Firefox and Opera browsers).
The Oncology Drug Information Database is an essential component in the effort to assure that cancer patients receive chemotherapeutic agents and supportive care therapies that reflect the current literature and state-of-the-art care.
Don Jewler, Director, Corporate CommunicationsPhone 301.984.9496, ext. 208, Email djewler@accc-cancer.org
